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Summary Sustained use of non-steroidal anti-inflammatory drugs (NSAIDs) may prevent colorectal cancer. However, the optimal drug,
period of efficacy and mechanism(s) of action are unknown. Experiments were undertaken to determine which of several NSAIDs would
modulate colon crypt cell proliferation or apoptosis when given during the initiation phase of 1,2-dimethylhydrazine (DMH)-induced rat colon
cancer. Colon crypts located both away from and over an aggregate of lymphoid nodules (ALN) were examined. Rats were injected with
aspirin, indomethacin, nabumetone, sodium salicylate, 16,16-dimethyl prostaglandin E2 or saline for 3 days and DMH or DMH vehicle on day
4 of each week for 8 weeks, then killed 3 days after the last DMH injection. At the time of killing, DMH had significantly increased crypt cell
proliferation but not apoptosis. There was significantly more cell proliferation and apoptosis in crypts over the ALN than away from the ALN.
Aspirin and salicylate increased proliferation and apoptosis in crypts over the ALN. Finally, the distributional peaks of cell proliferation and
apoptosis were shifted significantly closer together after DMH. Thus, DMH increases proliferation and alters the distribution of proliferating
and apoptotic cells in colon crypts early in carcinogenesis. Aspirin may suppress tumour incidence via salicylate by enhancing apoptosis in
carcinogen-initiated cells.
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Data from human epidemiological research (Thun, 1994;
Giovannucci et al, 1995) and from rodent experimental research
(Craven and DeRubertis, 1992; Reddy et al, 1993) have demon-
strated both correlative and direct evidence ofa role for aspirin and
possibly other non-steroidal anti-inflammatory drugs (NSAIDs) in
the prevention of colon and rectal cancer morbidity and mortality.
However, the optimal NSAID, the dose, the period ofefficacy and
the mechanism ofthis putative chemopreventive activity remain to
be established (Earnest et al, 1992; Giardiello et al, 1995).
One potential mechanism for this chemopreventive effect lies in
the ability of aspirin and other NSAIDs to inhibit prostaglandin
production by blocking the activity of one or both of the
prostaglandin endoperoxide G/H synthase (PGHS) isozymes,
PGHS-1 and PGHS-2 (Meade et al, 1993). PGHS-l is the constitu-
tive form of the enzyme and is expressed in most tissues, whereas
PGHS-2 is induced by mitogenic stimuli in inflammatory situa-
tions (Smith and DeWitt, 1996) and is expressed at high levels in
colon tumour tissue (Eberhart et al, 1994; Kargman et al, 1995;
Dubois et al, 1996). Aspirin covalently and irreversibly modifies
the cyclo-oxygenase active site of both PGHS-1 and PGHS-2 by
acetylation, whereas other NSAIDs reversibly block PGHS func-
tion and thus prostaglandin production via steric hindrance of the
cyclo-oxygenase active site (Smith and DeWitt, 1996).
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Several lines ofevidence implicate prostaglandin (PG) involve-
ment in colorectal cancer (Marnett, 1992). These include:
evidence that PGs stimulate proliferation of human colon cancer
cell lines in vitro and normal rodent colon epithelial tissue in vivo
(Qiao et al, 1995); evidence that progressively increased tissue
prostaglandin EB (PGE2) levels are associated with progression of
colon carcinogenesis (Pugh and Thomas, 1994); and a possible
immunosuppressive effect of PGE2 (Goodwin, 1981). Thus,
NSAID inhibition of intestinal prostaglandin production may have
a number ofdirect chemopreventive activities against the progres-
sion ofcolorectal cancer.
Other potential mechanisms for chemoprevention by NSAIDs
include alteration of colon epithelial cell proliferation and/or apo-
ptosis. A tumour is generally considered to be a lesion that arises
as aresult ofan imbalance between cell proliferation and celldeath.
Increased epithelial cell proliferation is an established risk factor
for colon cancer development (Deschner and Maskens, 1982;
Wright and Alison, 1984; Cameron et al, 1990). NSAIDs have
been shown to reduce cell proliferative parameters in colon crypts
(Barnes et al, 1995) and to stall cultured colon adenocarcinoma
cells in the GO/GI phase of the cell cycle (Shiff et al, 1996).
NSAIDs may also restore normal colon mucosal homeostasis in
situations of increased proliferation by inducing apoptotic cell
death (Pasricha et al, 1995; Shiff et al, 1995; 1996).
This report examines whether NSAIDs, specifically aspirin,
indomethacin or nabumetone, would prevent initial preneoplastic
changes in colon epithelial cell proliferation or apoptosis when
administered only during the initiation phase of 1,2-dimethyl-
hydrazine (DMH)-induced rat colon cancer. Either aspirin and/or
its metabolite, salicylic acid, could be the active molecule in colon
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cancer chemoprevention; thus, this study included both aspirin and
sodium salicylate treatment groups. In addition, 16,16-dimethyl-
prostaglandin E, (dmPGE2), a stable PGE, analogue that has been
shown to stimulate proliferation ofcolonocytes both in vitro and in
vivo (Qiao et al, 1995), was tested as a positive control for inhibi-
tion of prostaglandin synthesis by NSAIDs. The effects of these
drugs on cell proliferation and apoptosis were examined in rat
colon crypts located both over the rat distal colon aggregate of
lymphoid nodules (ALN, a site ofrapid epithelial cell proliferation
and of high risk for adenocarcinoma occurrence; Hammann et al,
1992; Cameron et al, 1996) and away from an ALN. Finally, this
report demonstrates: (a) the simultaneous use of the cell prolifera-
tive and apoptotic indices in colon crypts; and (b) that the distribu-
tion ofproliferative and apoptotic cells in colon crypts can be used
as an early biomarker ofneoplastic change.
MATERIALS AND METHODS
Animals
Male Sprague-Dawley rats were purchased at 2 months of age
from Harlan Sprague-Dawley (Indianapolis, IN, USA) 4 weeks
before the experiment. Rats had free access to Teklad ML485 Rat
Diet (Teklad/HSD, Madison, WI, USA) and water before and
throughout these studies. The rats were housed in wire-bottom
cages to prevent coprophagy. All experimental procedures
described below were approved by the Institutional Animal Care
Program of the University of Texas Health Science Center (San
Antonio, TX, USA).
Reagents
The following materials were used in these studies: DMH, acetyl-
salicylic acid (ASA, aspirin), sodium salicylate, indomethacin,
and 16,16-dimethyl-prostaglandin E, (dmPGE2, a stable PGE2
analogue) were purchased from Sigma (St Louis, MO, USA);
nabumetone was a generous gift from SmithKline Beecham, King
of Prussia, PA, USA; an antiproliferating cell nuclear antigen
(PCNA) monoclonal antibody (PC10 clone) was purchased from
Signet (Dedham, MA, USA); and the Apoptag kit (purchased from
Oncor, Gaithersburg, MD, USA) was used in the TdT UDP
nucleotide end-labelling (TUNEL) assay for fragmented DNA
ends. All other chemicals were of the highest grade available and
were obtained commercially. DMH vehicle contained 0.9% sodium
chloride and 0.18% EDTA, pH 6.5, and all other solutions were
prepared and diluted with normal saline (0.9% codium chloride
solution, pH 6.5). All solutions were prepared 1 h before injection.
Experimental protocol
After 4 weeks of acclimation and monitoring, rats were randomly
divided into one of six treatment groups (n = 12 per group) and
were given a single s.c. injection of either saline (4 ml kg-' body
weight), acetylsalicylic acid (aspirin, a non-specific PGHS
inhibitor, 50 mg kg-'), sodium salicylate (the degradation product
ofaspirin, 50 mg kg-'), indomethacin (a selective PGHS-1 inhibitor,
4 mg kg-'), nabumetone (a selective PGHS-2 inhibitor, 100 mg kg-')
or dmPGE2 (a major colon prostaglandin, 50 mg kg-') on three
successive mornings. Aspirin, indomethacin and nabumetone were
given in dosages that have significant anti-inflammatory action and
that would significantly inhibit PG biosynthesis (Meade et al, 1993;
Figure 1 Photomicrographs of representative apoptotic figures
(arrowheads) found at different points along the crypt column in haematoxylin
and eosin-stained 4-,um sections of rat colon tissue. Bar= 20 im
Laneuville et al, 1994). DmPGE2 was administered at a dose that
has been shown to confer mucosal protection against NSAID-
induced injury in the gastrointestinal tract (Lee and Feldman,
1992). On the fourth morning, halfofthe rats in each group (n = 6)
were given a s.c. injection of DMH (12 mg base per kg bw)
and the other half were injected with DMH vehicle alone
(4 ml kg-'). This weekly pattern was repeated for 8 weeks
according to an established protocol for inducing rat colon cancer
(Cameron et al, 1990). At the start of week 9 (i.e. 3 days after the
last DMH dose), the rats were anaesthetized and killed by decapita-
tion. Immediately afterkilling, each colon was resected, rinsed with
ice-cold phosphate-buffered saline (PBS, pH 7.4) and examined
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macroscopically. A 2-cm length ofbowel was flash-frozen in liquid
nitrogen and stored at -80°C for radioimmunoassay of cyclo-
oxygenase activity, as described previously (Redfern et al, 1987;
Lee and Feldman, 1992), using the formation of PGE2 from
radiolabelled arachidonic acid as an end point. The remaining distal
colon was stretched to remove longitudinal folds and pinned flat,
serosa side down, on a piece ofcork board. The pinned colons were
fixed in 10% buffered formalin for 2 h, then stored in 70% ethanol.
Rats that received DMH gained significantly less weight (P < 0.05)
than the DMH vehicle control rats during this 8-week period
(82.8 ± 9.89 and 118 ± 8.11 g ± s.e.m. respectively), but there was
no significant difference in weight gain due to the other drug
treatments (data not shown).
Proliferative analyses
Transverse segments of the rat descending colon were excised
from approximately 3 cm proximal to the anus through the distal
colon ALN (over the distal ALN) and from 6 cm proximal to the
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anus (away from an ALN) and from approximately 3 cm proximal
to the anus through the distal colon ALN (over the ALN), and
prepared for histology. Four-,um-thick cross-sections of each
paraffin-embedded colon segment were cut, mounted on polyly-
sine-coated glass slides, deparaffinized through a series of xylene
and graded ethanol washes and incubated with an anti-PCNA
monoclonal antibody using routine immunohistochemical proce-
dures, as previously described (Hardman and Cameron, 1994).
The validity of using PCNA immunohistochemistry for assess-
ment ofcell proliferation in the colon epithelium has been reported
previously (Risio et al, 1993; Bostick et al, 1994). As PCNA
exhibits a gradation of nuclear staining in formalin-fixed tissue,
strict selection criteria were used in which the number and crypt
position of only the most intensely stained cells were recorded.
Crypts were included in the assessment if they spanned from
immediately adjacent to the muscularis mucosae to the surface
epithelium, with the entire lumen ofthe crypt visible. Cell prolifer-
ation parameters were scored for at least 12 crypts per rat in each
colon region as reported previously (Hardman and Cameron,
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Figure 2 Frequency distributions of proliferative cells identified by positive PCNA staining, apoptotic cells identified by strict morphological criteria, and of crypt
heights in midaxially sectioned colon crypts from rats which were given eight weekly injections of DMH (-------) or DMH vehicle ( ). Data are from crypts
located (A) approximately 6cm from the anus or (B) directly over the distal colon ALN, approximately 3cm from the anus. For presentation, distributions have
been smoothed over five cell positions along the x-axis. The numerical distributional means are presented in Table 4
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Table 1 Effects of different drug treatments on the mean (+ 95% confidence
intervals) number of PCNA positively stained cells per midaxial crypt section
as scored in crypts located either over or away from the distal aggregate of
lymphatic nodules
Group DMHa Away ALNb Over ALN
Saline - 2.99 + 1.18 6.94 + 1.89
Saline + 6.67 ± 2.52 6.09 + 2.44
Aspirin + 3.70 ± 1.69 c16.61 ± 6.55
Salicylate + 4.83 ± 2.48 cl 9.54 + 4.99
Indomethacin + 3.57 ± 0.92 10.21 + 1.50
Nabumetone + 6.82 + 2.35 11.48 ± 6.81
dmPGE2 + 5.88 + 2.91 11.94 + 1.43
a(-) DMH vehicle (+) DMH (12 mg base per kg body weight) s.c. once a week
for 8 weeks, with six rats per group. bAway, crypts located at least 3 cm from
an ALN; over, crypts located within three crypt widths of a lymphatic nodule.
cSignificantly higher mean than means of other treatment groups:
P< 0.05.
1994; Barnes et al, 1995). A single column ofcells was counted in
each complete mid-axially sectioned crypt from the base up each
side to the mouth of the crypt. The recorded parameters were the
following: total height from the base to the mouth of the crypt in
number of cells (CH), total number of darkly stained PCNA-
positive cells per crypt, and position of each positively stained
cell along the crypt column.
Scoring of apoptosis
Apoptosis was scored on haematoxylin and eosin-stained,
complete mid-axially sectioned colon crypts, as described previ-
ously (Potten et al, 1992), using different sections from the same
tissue blocks used in assessing crypt cell proliferation. At least 30
crypts away from an ALN and 15 crypts over the distal ALN per
rat were divided along the long axis into two half-crypts, which
were scored separately for each ofsix rats per treatment group (i.e.
at least 360 half-crypts away ALN and 180 half-crypts over ALN).
Each apoptotic event was identified using the established morpho-
logical features of nuclear marginalization of chromatin, conden-
sation of the cytoplasm, cell shrinkage and membrane blebbing,
and final fragmentation of the cell into apoptotic bodies (Potten,
1992) using a light microscope (Figure 1). The position of each
apoptotic event in number of cells from the base of the crypt was
recorded. Apoptotic bodies were occasionally seen engulfed by
neighbouring cells or extruded into the crypt lumen. If several
apoptotic bodies were grouped around a single cell position, the
cluster was recorded as a single apoptotic event. In addition, if a
clear distinction could not be made between an apoptotic cell
and an invading intraepithelial lymphocyte, the figure was not
recorded. Only apoptotic cells within the crypt length and not at
the lumenal surface between crypts, where considerable cell death
occurs, were included in this assessment.
In addition, two techniques for identifying apoptotic cells were
compared for general agreement. One set of slide-mounted colon
tissue sections from the saline, DMH vehicle control group was
stained with haematoxylin and eosin and apoptotic cells were
identified by morphological characteristics. Representative exam-
ples ofapoptosis are shown in Figure 1. A second set of slides was
used for digoxigenin labelling and direct immunoperoxidase
detection of 3'-OH cut DNA ends that usually occur during the
apoptotic process. The in situ detection was performed according
to the manufacturer's instructions (Apoptag kit, Oncor).
Statistical analysis
All statistical analyses were performed using either SAS (SAS
Institute, Cary, IL, USA) or PRISM (GraphPad Software, San
Diego, CA, USA) statistical software. Unless otherwise stated,
statistical significance was accepted when P < 0.05. Multiway
analysis of variance (ANOVA) and Student-Newman-Keuls
(SNK) multiple range tests were performed for comparison of the
effects ofthe NSAID treatment group and location over an ALN or
away from an ALN on cell proliferative and apoptotic indices
within colon crypts. Student's t-test was used for comparison of
the two methods ofapoptosis assessment.
Plots of either proliferative or apoptotic cells exhibited Poisson
distributions as determined by the Kolmogorov-Smirnov good-
ness-of-fit test. However, the square root transformed data did not
differ from a normal distribution, so parametric statistical compar-
isons of PCNA-stained cells per crypt and crypt apoptotic index
were performed on the transformed data. Crypt height was found
to be normally distributed and thus no transformation was neces-
sary. t-tests between the mean cell position of the transformed
frequency distributions ofproliferative or apoptotic cell along the
length of the colon crypt were used as a measure of central
tendency for determining the effect of DMH treatment and/or
location over or away from the distal ALN on the intracrypt distri-
bution ofproliferative or apoptotic cells. For simplicity of presen-
tation, these frequency distributions were smoothed over five
consecutive cell positions along the length ofthe crypt in Figure 2.
Table 2 Statistical comparison of crypt apoptotic indices and distribution of apoptosis in normal rat colon crypts both over an ALN and away from an ALN using
identification of apoptotic cells by morphological criteria vs identification by in situ detection of digoxigenin-labelled 3'-OH DNA ends
Apoptotic cells/
midaxial crypt sectiona Distribution Meansb
Detection Method Away ALN Over ALNc Away ALN Over ALNd
Morphologye 0.186 0.684 14.39 ± 3.03 21.12+ 1.47
in situ DNA end-labelling 0.075 0.427 15.79 ± 5.17 21.23 + 4.59
aThe mean number of apoptotic cells per midaxial crypt section from six rats per group and at least 60 half-crypts per rat away from the ALN, and 30 half-crypts
per rat over the ALN. bThe mean of the distribution of apoptotic cells by cell position (± 95% Cl) from the crypt base. cOver the ALN significantly greater than
away from the ALN: P < 0.05. dOver the ALN significantly greater than away from the ALN: P< 0.05. eUse of morphological criteria on H&E-stained tissue
sections identified significantly more apoptotic cells per midaxial crypt section than did in situ DNA end-labelling: P< 0.05.
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RESULTS
Proliferative parameters
The number of PCNA positively stained cells per midaxial crypt
section was evaluated in each colon at the end of an 8-week initia-
tion period as a surrogate end point biomarker (or biomarker) for
risk of colon cancer development (Table 1). Two-way ANOVA
evaluating the influence of location of crypts either over or away
from the ALN and the influence ofNSAID treatment on cell prolif-
eration in DMH-treated rats revealed that both variables indepen-
dently and significantly increased the number ofproliferating cells
per crypt, with a significant interaction between the two variables.
Subsequent one-way ANOVA demonstrated that the interaction
was due to the significant increase in proliferating cells per crypt in
the aspirin and salicylate treatment groups selectively in crypts over
the ALN. There were no significant changes in proliferative para-
meters due to indomethacin, nabumetone or dmPGE2.
Effect of DMH and NSAID intervention on total
cyclooxygenase activity
A radioimmunoassay for PGE2 production from radiolabelled
arachidonic acid was performed on colon tissue from each experi-
mental rat to determine if administration of PGHS inhibitors,
under the current protocol, caused any long-term (i.e. several days)
alteration in colon mucosal cyclo-oxygenase activity. Two-way
ANOVA showed that there were no significant differences in PGE2
production due to DMH treatment 3 days after the last dose of
DMH [50.75 ± 18.45 (DMH) vs 41.80 ± 14.65 (no DMH) pg PGE2
mg-' colon tissue min-' ± 95% confidence interval] or due to the
different drug treatments 4 days after the last dose ofthe drug (data
not shown).
Comparison of two methods for identifying apoptotic
cells
A comparison between apoptotic counts within the crypt as
assessed by morphology and as assessed by in situ end-labelling of
the fragmented DNA ends was conducted on colon tissue sections
from the DMH vehicle/saline control group. There were quantita-
tive differences in the apoptotic index as assessed by these two
methods (Table 2). Scoring by the morphological criteria gave a
higher apoptotic index than the DNA end-labelling method.
However, statistical analyses showed that there was no significant
difference in the mean of the spatial frequency distribution of
apoptotic cells within the crypt due to the method of detection.
Both techniques indicated that the number of apoptotic cells per
midaxial crypt section and the mean of the frequency distribution
ofapoptotic cells were higher in crypts located over the ALN than
in crypts away from the ALN.
The results ofthe morphological index were approximately that
ofthe estimated normal rate ofapoptosis in mouse colon epithelial
cells (0.2 apoptotic bodies/midaxial crypt section; Potten, 1992).
The DNA end-labelling method may identify fewer apoptotic cells
than morphology because this technique: (a) exhibits marked vari-
ability of results; (b) is highly dependent on the conditions of the
labelling procedure; and (c) appears to be difficult to use in the
intestine (Que and Gores, 1996). Owing to the greater accuracy
and reliability of morphological criteria, this method was used for
identification of apoptotic cells for the quantitative apoptotic data
presented in the remainder ofthis report.
Quantitation of crypt apoptosis as influenced by DMH,
NSAIDs or location in the colon
The mean number of apoptotic cells per midaxial colon crypt
section in each treatment group were compared by three way
ANOVA for differences due to the variables of: (a) DMH treat-
ment; (b) location in colon (over or away from the ALN); and (c)
NSAID treatment. DMH treatment did not significantly affect the
occurrence ofapoptosis in colon epithelial cells as assessed 3 days
after the last DMH dose (data not shown), but the mean apoptotic
index was significantly higher in crypts located over the distal
ALN (0.754 apoptotic cells/crypt section) than in crypts located
away from the distal ALN (0.219 apoptotic cells/crypt section) as
shown in Table 3. There was no significant difference between the
apoptotic indices ofthe DMH/NSAID treatment groups away from
the ALN. However, over the ALN the mean apoptotic index ofthe
salicylate treated group was significantly higher than in all other
treatment groups (P < 0.001).
Correlation of apoptosis and proliferation
Linearregression was used to testforcorrelation between the crypt
apoptotic index and the cell proliferative index in crypts of indi-
vidual treatment groups both with and without DMH and in crypts
located over and away from the distal ALN. There were no signif-
icant correlations by linear regression analyses between cell birth
(proliferation) and cell death (apoptosis) within crypts (data not
shown). This lack of correlation may be due to the assessment of
apoptotic cells only within the crypt column. Considerable cell
death occurs at the luminal surface of the colon epithelium and
apoptotic cells on the luminal surface were not assessed.
Table 3 Statistical analyses of the mean number of apoptotic cells per H&E-stained midaxial colon crypt section in DMH-treated rats
Apoptotic cells/midaxial crypt sectiona Row
means
Saline Aspirin Salicylate Indomethacin Nabumetone dmPGE2
Away ALNb 0.220 0.218 0.222 0.203 0.207 0.247 0.219
Over ALNc 0.738 0.783 0.973d 0.636 0.674 0.717 0.754
aMean number of morphologically apoptotic epithelial cells along the crypt column length from six untreated control rats per group and at least 60 half-crypts
per rat away from the ALN, and 30 half-crypts per rat over the ALN. bAway ALN, at least 3 cm from a lymphatic nodule; over ALN, within three crypt widths of
a lymphatic nodule. cOver the ALN significantly greater value than away from the ALN: P< 0.05. dSalicylate group was significantly different from all other
groups: P < 0.05.
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Table 4 Mean (± 95% confidence intervals) position, in number of cells from the crypt base, of the frequency distributions of: PCNA-positive proliferative cells;
morphologically identified apoptotic cells; and crypt height in the descending colon of rats
Location DMHa nb Proliferative cells Apoptotic cells Crypt height
Away ALN - 717 7.34 ± 0.26 15.73 ± 1.29 30.10 ± 0.22
+ 440 d9.43 ±0.40 d14.00 ± 1.22 d32.30 ± 0.30
Over ALNc _ 340 11.26 ± 0.40 21.65 ± 1.40 38.32 ± 0.46
+ 308 d13.46 ± 0.43 d19.54 ± 1.41 e41.92 ± 0.54
a(_) DMH vehicle (+) DMH (12 mg base per kg body weight) s.c. once a week for 8 weeks. bNumber of crypts evaluated for proliferative cells, apoptotic cells,
and crypt height. cMean position of proliferative cells and apoptotic cells from the crypt base, and the mean colon crypt height were significantly greater over the
ALN than away from the ALN, both with and without DMH. dSignificant change from the non-DMH group. Square root transformation was used to normalize
data, then the means were compared using the unpaired t-test. Untransformed data are presented in the table. eSignificant change from the non-DMH group
when compared using the unpaired t-test.
Distribution of proliferating cells and apoptotic cells in
colon crypts
There were no significant differences between NSAID treatment
groups in the distribution of PCNA-positive cells, the distribution
ofapoptotic cells along the length ofthe crypt, or in crypt height in
number of cells (data not shown). Therefore, distributional data
from all treatment groups were combined for analyses of the
effects ofcrypt location (over vs away from ALN) and DMH treat-
ment on the frequency distributions of proliferating cells and of
apoptotic cells along the crypt length, and of mean crypt height
(Figure 2). Proliferative cells were located mainly in the lower
one-third to two-thirds of the crypt, whereas apoptotic cells were
found at every cell position along the length of the crypt.
Comparison of the means of the distributions of proliferation,
apoptosis and crypt height using the t-test showed that the means
of all three distributions were higher in crypts located over the
ALN than in crypts located away from the ALN whether or not the
rats were exposed to DMH (Table 4). DMH treatment resulted in:
(a) a significant shift in the mean position of proliferative cells
towards the top of the crypt; (b) a significant shift in the mean
position of apoptotic cells towards the base ofthe crypt; and (c) a
significant increase in the mean crypt height (Table 4). The magni-
tude of this DMH effect on the mean position of proliferative and
apoptotic cells was similar in crypts over and away from ALN,
possibly indicating a similar response to the carcinogen in both
regions ofthe colon.
DISCUSSION
NSAIDs and ALN on cell proliferation
Colon crypt epithelial cell proliferation was evaluated at the end of
an 8-week initiation period in this rat colon cancer model, specifi-
cally 4 days after the last NSAID dose and 3 days after the last
DMH dose. This recovery time was necessary to allow the epithe-
lium to reach a steady state after DMH injection (Wright and
Alison, 1984; Deschner, 1987; Cameron et al, 1990), and to enable
the evaluation oflonger lasting rather than immediate effects ofthe
other drugs. Given the relatively short half-lives of the drugs
administered (Insel, 1996) and the lack ofany significant difference
in total cyclo-oxygenase activity between the treatment groups, any
changes in proliferation may have been due to a long-term influ-
ence ofthe NSAID rather than to a short-term NSAID suppression
ofprostaglandin synthesis. However, 4 days afterthe lastdose there
was no significant change in crypt proliferation due to
indomethacin, nabumetone or dmPGE2 treatment when compared
with the saline/DMH control group. Thus, it is probable that these
drugs do not have a long-lasting influence on colon epithelial cell
proliferation. There were significant increases in the mean number
of proliferating cells per crypt 4 days after salicylate or aspirin
treatment, which occurred selectively in crypts located over the
ALN, although the saline/DMH control group had a spuriously low
PCNA index. The relevance ofthese findings is discussed below in
relation to altered apoptosis within the same colon location and
treatment groups. Finally, we would like to point out that although
we have used strict counting criteria to avoid excessive prolifera-
tive counts, there are potential limitations to using PCNA as a
proliferative marker, such as the long half-life of PCNA and its
expression during DNA repair, leading to the labelling of non-
proliferative cells (Hall et al, 1990; Risio et al, 1994).
Crypt cell proliferation was significantly higher following
DMH treatment, and also significantly higher in crypts located
over an ALN than in crypts located away from an ALN. These
findings were expected based on previous reports (Hardman and
Cameron, 1994; Barnes et al, 1995). As there is a strong correla-
tion between sites oflymphatic nodules and sites ofhighincidence
ofcolon and rectal tumours in both rodents (Hammann et al, 1992;
Cameron et al, 1996) and humans (Shamsuddin et al, 1982; Glick
et al, 1988; Hillon et al, 1990), it seems important to evaluate the
ability ofpotential chemopreventive agents to modulate surrogate
end point biomarkers in colon crypts in the region of the ALN if
we are to be able to predict the efficacy ofthe agent at preventing
colon cancer.
Alterations in crypt apoptotic index
The transformation ofcolorectal epithelium to carcinoma has been
associated with a progressive inhibition of apoptosis (Bedi et al,
1995; Payne et al, 1995) and an increase in the proliferative- apop-
totic cell ratio (Koike, 1996). Apoptosis within the crypt column is
thought to eliminate crypt cells containing random and/or induced
genetic defects (Potten, 1992). Perturbation of the normal pattern
of apoptosis may, therefore, serve as an early surrogate end point
biomarker of both carcinogen exposure and disease progression.
We have for the first time used alteration in the number and the
distribution of apoptotic cells within rat colon crypts to indicate
both early preneoplastic changes and the efficacy of chemo-
preventive interventions.
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The findings reported here reveal an overall significant increase
in cell proliferation in the midaxially sectioned colon crypts 3 days
after repeated carcinogen exposure without a significant persistent
increase in the apoptotic index. Increased proliferation without
increased cell death might be expected to result in an accumulation
of cells in the crypt column height, which was indeed observed.
However, conclusions cannot be drawn from the present data on
altered crypt cell volume. It is likely that the observations reported
here of an overall increase in proliferation and decrease apoptotic
cell death within the crypt column of midaxially sectioned colon
crypts reflect a perturbation from the normal crypt homeostasis
after repeated carcinogen exposures.
Treatment with aspirin or sodium salicylate resulted in
increased proliferation and a higher apoptotic index (significant
for salicylate only) selectively in crypts over the distal ALN.
Considering the fact that salicylic acid, the metabolite of aspirin,
has a much longer biological half-life than does aspirin (Insel,
1996), and that evaluations were performed 4 days after the last
aspirin dose, one can conjecture that the observed aspirin effect
may actually be due to exposure to salicylate rather than as a direct
action of aspirin itself. In support of this hypothesis, in vitro
studies report that salicylate treatment (Elder et al, 1996) but not
aspirin treatment (Shiffet al, 1996) induced apoptotic cell death in
cultured epithelial cells. Increased epithelial cell turnover rate
(apoptosis and proliferation) after carcinogen exposure may be
indicative of self-screening, i.e. identification and elimination of
cells with irreparable genetic damage, resulting in compensatory
increased cell proliferation. Thus, one potential cancer chemopre-
ventive mechanism of action for aspirin may be to increase death
of damaged cells via salicylate, specifically in the crypts located
over the distal ALN, which are at high risk for developing cancer
(Hardman and Cameron, 1994; Cameron et al, 1996). Indeed,
induction of apoptosis has been proposed as the primary mecha-
nism of action of the NSAID sulindac and its sulphide and
sulphone derivatives in countering familial adenomatous poly-
posis (Pasricha et al, 1995; Shiffet al, 1995).
Distribution of proliferative and apoptotic cells within
colon crypts
DMH appears to effect a long-term (i.e. at least 3 days) coordi-
nated, spatial alteration in the distribution of cell birth and cell
death within the crypt. The significant reduction in the relative
distance between the peaks of the distribution of cell proliferation
and cell death after DMH treatment may be indicative of greater
apoptotic cell death of the less differentiated progenitors of
epithelial cells that are found deeper in the crypt. Upon repeated
carcinogen exposure, crypt stem cells are likely to sustain and
accumulate genetic damage, but are hypothesized to be unable to
eliminate themselves by undergoing apoptosis due to high levels
of Bcl-2 expression (Merritt et al, 1995). The progeny of stem
cells, however, lose this high level of Bcl-2 expression (Merritt et
al, 1995) and gain the capacity for self-screening and subsequent
elimination of damaged cells through induction ofapoptosis. With
a greater number of progeny cells dying earlier in the differentia-
tion process, fewer cells remain to repopulate the crypt. Thus, the
remaining cells must undergo a greater number of divisions to
maintain the normal number ofcrypt cells. The result is a delay in
terminal cell differentiation, the occurrence of proliferating cells
higher in the crypt column, and a significant expansion of the
crypt proliferative zone after carcinogen exposure (Deschner and
Maskens, 1982; Wright and Alison, 1984). Eventually, some cells
with genetic damage are likely to escape this self-screening mech-
anism, leading to proliferation ofcarcinogen-initiated cells and the
eventual development of intraepithelial neoplasms. Aspirin or
salicylate may somehow enhance the self-screening capacity and
subsequently the elimination ofdamaged cells.
CONCLUSION
Aspirin and salicylate are hypothesized to enhance self-screening
of DMH-initiated colon epithelial cells selectively in crypts
located over the distal aggregate of lymphoid nodules, a site at
high risk for adenocarcinoma development, suggesting a possible
anti-cancer mechanism of action for aspirin. In the present model
ofDMH-induced rat colon cancer, administration ofindomethacin
and nabumetone did not alter surrogate end point biomarkers when
evaluated 4 days after the last NSAID dose, suggesting that these
NSAIDs may not have the same chemopreventive ability as
aspirin. Perturbation ofthe normal colon crypt apoptotic index and
the normal distribution of apoptotic cells within the crypt were
successfully used as surrogate biomarkers of colon carcinogen
exposure. Given the importance ofboth cell birth and cell death in
the carcinogenic process, colon crypt epithelial cell apoptosis in
conjunction with cell proliferation should be evaluated in studies
ofcolon carcinogenesis.
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ABBREVIATIONS
ALN, aggregate of lymphoid nodules; ANOVA, analysis of vari-
ance; CH, crypt height; DMH, 1,2-dimethylhydrazine; dmPGE,,
16,16-dimethyl prostaglandin E,; NSAID, non-steroidal anti-
inflammatory drug; PCNA, proliferating cell nuclear antigen;
PGE2, prostaglandin E2; PGHS, prostaglandin endoperoxide H
synthase; SNK, Student-Newman-Keuls; TdT, terminal deoxy-
nucleotidal transferase.
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